Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1Genitourinary 1Gastrointestinal 1Breast 1

Conditions

Prostatic Neoplasms 1Primary Care 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Fallopian Tube Neoplasms 1Endometrial Neoplasms 1Colorectal Neoplasms 1Breast Neoplasms 1

Interventions

pembrolizumab 45Paclitaxel 42Carboplatin 34Specimen Handling 18Bevacizumab 18Letrozole 15lenvatinib 13Magnetic Resonance Spectroscopy 13dostarlimab 11Cisplatin 11Biopsy 11Taxes 10olaparib 9Fulvestrant 9Doxorubicin 9Megestrol Acetate 8Docetaxel 8durvalumab 7atezolizumab 7abemaciclib 7Nivolumab 7Gemcitabine 7Blood Specimen Collection 7palbociclib 6Oxaliplatin 6Observation 6Fluorouracil 6niraparib 5Surveys and Questionnaires 5Progestins 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Endometrial Neoplasms × Darbepoetin alfa × 1 year × Clear all
NCT06184867 2026-03-06

CATALYST

Rutgers, The State University of New Jersey

Phase NA Completed
50 enrolled
BreastGastrointestinalGenitourinaryGynecologic

Breast Neoplasms, Fallopian Tube Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡